GlobeNewswire·Nov 6, 2026, 7:00 AM ET

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix, Inc. granted inducement equity awards to eight newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan.
The awards became effective on November 2, 2026, in compliance with Nasdaq Listing Rule 5635(c)(4).
The grant consists of non-statutory stock options for 35,775 shares and restricted stock units for 11,725 shares.
Stock options carry an exercise price of $6.73 per share, based on the closing price on the grant date, with a ten-year term.
Stock option vesting occurs over four years, starting with 25% on the first employment anniversary followed by equal monthly installments for the remaining three years.
Restricted stock units vest over three years in equal annual installments on the first, second, and third anniversaries of the grant date.
Both award types are subject to the recipient's continued service through applicable vesting dates.
Ocular's pipeline includes AXPAXLI (OTX-TKI), an investigational product in Phase 3 trials for wet AMD and diabetic retinal disease.
The company markets DEXTENZA, an FDA-approved corticosteroid, and is evaluating next steps for its investigational glaucoma candidate OTX-TIC.